INMUNE BIO INC. 2024-2025 Proxy Voting Records

Description as filed by funds: To elect the five directors set forth below to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified: J. Kelly Ganjei

INMUNE BIO INC.’s own tally for this item (“Elect Director: J. Kelly Ganjei”): 10,179,113 for, 682,903 withheld, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Stockholders elected each of the following nominees as directors to hold office until the next meeting of the Company's stockholders and until his or her successor is elected and qualified.”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 27 asset managers below reported 41,743 for, 66,746 withheld.

Showing the 25 largest of 27 asset managers. All 27 are in the interactive database (link above).

Description as filed by funds: To elect the five directors set forth below to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified: Marcia Allen

INMUNE BIO INC.’s own tally for this item (“Elect Director: Marcia Allen”): 10,135,837 for, 726,179 withheld, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Stockholders elected each of the following nominees as directors to hold office until the next meeting of the Company's stockholders and until his or her successor is elected and qualified.”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 27 asset managers below reported 38,579 for, 69,910 withheld.

Showing the 25 largest of 27 asset managers. All 27 are in the interactive database (link above).

Description as filed by funds: To elect the five directors set forth below to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified: Raymond J. Tesi, M.D.

INMUNE BIO INC.’s own tally for this item (“Elect Director: Raymond J. Tesi, MD”): 10,338,962 for, 523,054 withheld, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Stockholders elected each of the following nominees as directors to hold office until the next meeting of the Company's stockholders and until his or her successor is elected and qualified.”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 27 asset managers below reported 84,225 for, 24,264 withheld.

Showing the 25 largest of 27 asset managers. All 27 are in the interactive database (link above).

Description as filed by funds: To elect the five directors set forth below to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified: Scott Juda, J.D.

INMUNE BIO INC.’s own tally for this item (“Elect Director: Scott Juda, JD”): 10,322,697 for, 539,319 withheld, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Stockholders elected each of the following nominees as directors to hold office until the next meeting of the Company's stockholders and until his or her successor is elected and qualified.”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 27 asset managers below reported 84,377 for, 24,112 withheld.

Showing the 25 largest of 27 asset managers. All 27 are in the interactive database (link above).

Description as filed by funds: To elect the five directors set forth below to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified: Timothy Schroeder

INMUNE BIO INC.’s own tally for this item (“Elect Director: Tim Schroeder”): 10,337,066 for, 524,950 withheld, per its Form 8-K filed June 10, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Stockholders elected each of the following nominees as directors to hold office until the next meeting of the Company's stockholders and until his or her successor is elected and qualified.”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 27 asset managers below reported 86,305 for, 22,184 withheld.

Showing the 25 largest of 27 asset managers. All 27 are in the interactive database (link above).

Description as filed by funds: Election of the directors named in the proxy statement as set forth below: J. Kelly Ganjei

INMUNE BIO INC.’s own tally for this item (“Elect Director: J. Kelly Ganjei”): 9,627,979 for, 836,743 withheld, per its Form 8-K filed July 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Stockholders elected each of the following nominees as directors to hold office until the next meeting of the Company's stockholders and until his or her successor is elected and qualified.”
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 9 asset managers below reported 179,222 withheld.

Description as filed by funds: Election of the directors named in the proxy statement as set forth below: Marcia Allen

INMUNE BIO INC.’s own tally for this item (“Elect Director: Marcia Allen”): 9,477,214 for, 987,508 withheld, per its Form 8-K filed July 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Stockholders elected each of the following nominees as directors to hold office until the next meeting of the Company's stockholders and until his or her successor is elected and qualified.”
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 9 asset managers below reported 3,743 for, 175,479 withheld.

Description as filed by funds: Election of the directors named in the proxy statement as set forth below: Raymond J. Tesi, MD

INMUNE BIO INC.’s own tally for this item (“Elect Director: Raymond J. Tesi, MD”): 9,947,830 for, 516,892 withheld, per its Form 8-K filed July 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Stockholders elected each of the following nominees as directors to hold office until the next meeting of the Company's stockholders and until his or her successor is elected and qualified.”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 9 asset managers below reported 171,566 for, 7,656 withheld.

Description as filed by funds: Election of the directors named in the proxy statement as set forth below: Scott Juda, JD

INMUNE BIO INC.’s own tally for this item (“Elect Director: Scott Juda, JD”): 9,950,069 for, 514,653 withheld, per its Form 8-K filed July 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Stockholders elected each of the following nominees as directors to hold office until the next meeting of the Company's stockholders and until his or her successor is elected and qualified.”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 9 asset managers below reported 171,566 for, 7,656 withheld.

Description as filed by funds: Election of the directors named in the proxy statement as set forth below: Tim Schroeder

INMUNE BIO INC.’s own tally for this item (“Elect Director: Tim Schroeder”): 9,908,788 for, 555,934 withheld, per its Form 8-K filed July 19, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Stockholders elected each of the following nominees as directors to hold office until the next meeting of the Company's stockholders and until his or her successor is elected and qualified.”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 9 asset managers below reported 171,566 for, 7,656 withheld.

The 3 asset managers below reported 28,166 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: To approve the Second Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan.

INMUNE BIO INC.’s own tally for this item (“5. Approval of the Second Amended and Restated INmune Bio Inc. 2021 Stock Incentive Plan”): 9,929,340 for, 838,301 against — passed, per its Form 8-K filed June 10, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “As noted above, the stockholders approved the Amended Plan.”
Support: 92% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 28 asset managers below reported 36,922 for, 71,568 against.

Showing the 25 largest of 28 asset managers. All 28 are in the interactive database (link above).

Description as filed by funds: To approve, by non-binding advisory vote, the resolution approving named executive officer compensation.

INMUNE BIO INC.’s own tally for this item (“3. To approve, by non-binding advisory vote, the resolution approving named executive officer compensation”): 10,541,030 for, 224,831 against — passed, per its Form 8-K filed June 10, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The compensation of the Company's named executive officers was approved, by a non-binding advisory vote, as follows:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 27 managers: 101,927 for, 6,562 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports, all 76 managers: 819,500 for, 25,442 against, 4,047 1 year. Showing the 25 largest; every one is in the interactive database (link above).

Description as filed by funds: To approve, by non-binding advisory vote, the frequency of future non-binding advisory votes on resolutions approving future named executive officer compensation.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports, all 27 managers: 108,191 1 year, 298 3 year. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports, all 75 managers: 185,855 for, 491 against, 645,989 1 year, 10,473 3 year. Showing the 25 largest; every one is in the interactive database (link above).

Description as filed by funds: To ratify the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the year ending December 31, 2025.

INMUNE BIO INC.’s own tally for this item (“2. Ratification of Appointment of Independent Auditor”): 16,180,211 for, 93,889 against — passed, per its Form 8-K filed June 10, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Stockholders approved the ratification of the appointment of CBIZ CPAs P.C. as the Company's independent auditors for the fiscal year ending December 31, 2025.”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 27 asset managers below reported 108,489 for.

Showing the 25 largest of 27 asset managers. All 27 are in the interactive database (link above).

Description as filed by funds: To ratify the appointment of Marcum LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024.

INMUNE BIO INC.’s own tally for this item (“2. Ratification of Appointment of Independent Auditor”): 14,504,668 for, 7,406 against — passed, per its Form 8-K filed July 19, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Stockholders approved the ratification of the appointment of Marcum LLP as the Company's independent auditors for the fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 9 asset managers below reported 179,222 for.